Jitong Lou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jitong Lou has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Di Wu
Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, USA
3 shared publications - Gaith Nabil Droby
University of North Carolina
3 shared publications - Yang Yang
Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, USA
3 shared publications Abigail Shelton
Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, USA
2 shared publications- Breanna Mann
Affiliations Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, Eshelman Innovation, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
2 shared publications Chenghao Wang
Department of Biostatistics, University of North Carolina, Chapel Hill, USA
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 15 January 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (2) , 653-659
Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial
Obstructive sleep apnea (OSA) is associated with obesity and cardiovascular risk. The SURMOUNT-OSA master protocol comprised two, 52-week, randomized, double-blind, placebo-controlled phase 3 studies (study 1 and study 2) and demonstrated a significant reduction of a number of cardiometabolic risk measures in participants with OSA and obesity following treatment with tirzepatide. Here we report prespecified analysis of cardiometabolic risk measures in SURMOUNT-OSA. Post hoc analyses include changes in a homeostatic model assessment for insulin resistance and mediation analysis to determine the proportion of observed changes attributable to reductions in body weight, apnea–hypopnea index and sleep apnea-specific hypoxic burden. In both study 1 and study 2 of SURMOUNT-OSA, tirzepatide treatment was associated with greater alleviation of cardiometabolic risk factors than placebo. Independent mediation effect of changes in OSA metrics was observed on high-sensitivity C-reactive protein, homeostatic model assessment for insulin resistance and triglycerides. The combination of changes in weight and OSA metrics, as well as weight alone, had a significant mediation effect on systolic blood pressure, but there was no significant mediation effect of weight or OSA metrics observed on diastolic blood pressure. Based on the mediation analysis, treating both sleep-disordered breathing and obesity is likely required to optimize the treatment effect on cardiometabolic benefits for patients with moderate-to-severe OSA and obesity. The ClinicalTrials.gov registration number for this study is NCT05412004.
- 15 January 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (2) , 653-659
Top Cited PapersOpen AccessTirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial
Obstructive sleep apnea (OSA) is associated with obesity and cardiovascular risk. The SURMOUNT-OSA master protocol comprised two, 52-week, randomized, double-blind, placebo-controlled phase 3 studies (study 1 and study 2) and demonstrated a significant reduction of a number of cardiometabolic risk measures in participants with OSA and obesity following treatment with tirzepatide. Here we report prespecified analysis of cardiometabolic risk measures in SURMOUNT-OSA. Post hoc analyses include changes in a homeostatic model assessment for insulin resistance and mediation analysis to determine the proportion of observed changes attributable to reductions in body weight, apnea–hypopnea index and sleep apnea-specific hypoxic burden. In both study 1 and study 2 of SURMOUNT-OSA, tirzepatide treatment was associated with greater alleviation of cardiometabolic risk factors than placebo. Independent mediation effect of changes in OSA metrics was observed on high-sensitivity C-reactive protein, homeostatic model assessment for insulin resistance and triglycerides. The combination of changes in weight and OSA metrics, as well as weight alone, had a significant mediation effect on systolic blood pressure, but there was no significant mediation effect of weight or OSA metrics observed on diastolic blood pressure. Based on the mediation analysis, treating both sleep-disordered breathing and obesity is likely required to optimize the treatment effect on cardiometabolic benefits for patients with moderate-to-severe OSA and obesity. The ClinicalTrials.gov registration number for this study is NCT05412004.
- Open Access
- 8 September 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (12) , 6988-6998
Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study
Aims: To determine whether adults with type 2 diabetes (T2D) treated with retatrutide report greater changes in self‐reported appetite, dietary restraint, and disinhibition compared to placebo or dulaglutide and to examine associations with weight change. Materials and Methods: These pre‐specified exploratory analyses examined changes from baseline in Appetite Visual Analogue Scale (VAS) and Eating Inventory (EI) scores after 24 and 36 weeks of once‐weekly treatment with placebo, dulaglutide 1.5 mg, or retatrutide 0.5, 4, 8, or 12 mg in 275 adults with T2D. Changes from baseline with retatrutide were compared to those with placebo and dulaglutide. Post‐hoc correlations between changes in body weight and Appetite VAS/EI scores were also examined. Results: Compared with placebo, participants who received retatrutide ≥4 mg reported greater reductions from baseline in overall appetite, hunger, and prospective food consumption (l at Week 24 (all p p r = 0.28, r = 0.36, and r = 0.31, respectively). Conclusions: Perceived hunger and tendency to overeat (disinhibition) were reduced with higher doses of retatrutide, compared with placebo. Greater weight reduction was associated with decreased perceived hunger and disinhibition and increased dietary restraint. Plain Language Summary: What Is the Context and Purpose of this Research Study?: Retatrutide is a new treatment currently being developed for people with obesity and people with type 2 diabetes. This study compared the changes in appetite and eating behaviours of adults with T2D who were treated with retatrutide, dulaglutide (an alternative treatment), or placebo (i.e., no treatment). We examined changes in feelings of hunger, satisfaction and fullness, the desire to eat certain types of foods (e.g., sweet, salty or fatty foods), the tendency to overeat (e.g., when stressed), and conscious efforts to limit food intake. We also examined the potential link between changes in appetite or eating behaviours and changes in weight during retatrutide treatment. What Was Done?: Adults with type 2 diabetes who participated in this trial completed two questionnaires that measured their eating habits at several time points during the 36‐week period in which they received treatment. The questionnaire responses of people who received retatrutide each week (1–4 different doses) were compared with the responses of people who received no treatment (i.e., placebo) and of people who received dulaglutide treatment. Any potential links between the amount of weight reduction people experienced while receiving treatment during the study and their questionnaire responses were also examined. What Were the Main Results?: This study showed that adults with type 2 diabetes who received higher doses of retatrutide reported being less likely to feel hungry or overeat compared to those who received no treatment (i.e., placebo) or those who received dulaglutide. On average, people who experienced greater weight reduction also reported being less hungry and less likely to overeat. What Is the Originality and Relevance of this Study?: This is the first study to assess changes in appetite and eating behaviours of adults with type 2 diabetes who received retatrutide. Our results suggest that enhanced modification of eating behaviours with retatrutide may assist with weight reduction in adults with type 2 diabetes.
- 8 September 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (12) , 6988-6998
Open AccessAppetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study
Aims: To determine whether adults with type 2 diabetes (T2D) treated with retatrutide report greater changes in self‐reported appetite, dietary restraint, and disinhibition compared to placebo or dulaglutide and to examine associations with weight change. Materials and Methods: These pre‐specified exploratory analyses examined changes from baseline in Appetite Visual Analogue Scale (VAS) and Eating Inventory (EI) scores after 24 and 36 weeks of once‐weekly treatment with placebo, dulaglutide 1.5 mg, or retatrutide 0.5, 4, 8, or 12 mg in 275 adults with T2D. Changes from baseline with retatrutide were compared to those with placebo and dulaglutide. Post‐hoc correlations between changes in body weight and Appetite VAS/EI scores were also examined. Results: Compared with placebo, participants who received retatrutide ≥4 mg reported greater reductions from baseline in overall appetite, hunger, and prospective food consumption (l at Week 24 (all p p r = 0.28, r = 0.36, and r = 0.31, respectively). Conclusions: Perceived hunger and tendency to overeat (disinhibition) were reduced with higher doses of retatrutide, compared with placebo. Greater weight reduction was associated with decreased perceived hunger and disinhibition and increased dietary restraint. Plain Language Summary: What Is the Context and Purpose of this Research Study?: Retatrutide is a new treatment currently being developed for people with obesity and people with type 2 diabetes. This study compared the changes in appetite and eating behaviours of adults with T2D who were treated with retatrutide, dulaglutide (an alternative treatment), or placebo (i.e., no treatment). We examined changes in feelings of hunger, satisfaction and fullness, the desire to eat certain types of foods (e.g., sweet, salty or fatty foods), the tendency to overeat (e.g., when stressed), and conscious efforts to limit food intake. We also examined the potential link between changes in appetite or eating behaviours and changes in weight during retatrutide treatment. What Was Done?: Adults with type 2 diabetes who participated in this trial completed two questionnaires that measured their eating habits at several time points during the 36‐week period in which they received treatment. The questionnaire responses of people who received retatrutide each week (1–4 different doses) were compared with the responses of people who received no treatment (i.e., placebo) and of people who received dulaglutide treatment. Any potential links between the amount of weight reduction people experienced while receiving treatment during the study and their questionnaire responses were also examined. What Were the Main Results?: This study showed that adults with type 2 diabetes who received higher doses of retatrutide reported being less likely to feel hungry or overeat compared to those who received no treatment (i.e., placebo) or those who received dulaglutide. On average, people who experienced greater weight reduction also reported being less hungry and less likely to overeat. What Is the Originality and Relevance of this Study?: This is the first study to assess changes in appetite and eating behaviours of adults with type 2 diabetes who received retatrutide. Our results suggest that enhanced modification of eating behaviours with retatrutide may assist with weight reduction in adults with type 2 diabetes.
- Open Access
Differential roles of Rad18 in repressing carcinogen- and oncogene-driven mutagenesis in vivo
The DNA repair protein RAD18 activates ‘Y-family’ Trans-Lesion Synthesis (TLS) DNA polymerases that are DNA damage-tolerant and potentially error-prone. RAD18 is also frequently overexpressed and pathologically activated in cancer cells. However, the extent to which RAD18 shapes cancer genomes and impacts tumorigenesis is unclear. Therefore, we tested the effect of Rad18 status on chemically-induced and oncogene-driven tumorigenesis. In a chemically-induced oral carcinogenesis model, acute (2-16 days) 4NQO-treatment induces expression of Rad18 and TLS polymerase mRNAs in mouse oral epithelial cells prior to emergence of oral squamous cell carcinomas (OSCCs). Chronic (8 week) 4NQO-treatment leads to onset of oral tumors that is accelerated in Rad18 -/- mice when compared with Rad18 +/+ animals. Analysis of OSCC exomes reveals increased levels of G(C)>T(A) transversions in Rad18 -/- tumors when compared with Rad18 +/+ . Therefore, Rad18 promotes error-free bypass of 4NQO-induced DNA lesions and suppresses 4NQO-induced oral carcinogenesis. In a Kras G12D -induced lung carcinogenesis model, Rad18 -deficiency did not affect rates or incidence of oncogene-induced lung tumors or mutations. Taken together, we demonstrate that Rad18 has context-specific tumor-suppressive activity. Given the prevalence of 4NQO-like environmental exposures, RAD18 is highly likely to shape human cancer genomes and perhaps influence other aspects of the tumorigenic process.
Open AccessDifferential roles of Rad18 in repressing carcinogen- and oncogene-driven mutagenesis in vivo
The DNA repair protein RAD18 activates ‘Y-family’ Trans-Lesion Synthesis (TLS) DNA polymerases that are DNA damage-tolerant and potentially error-prone. RAD18 is also frequently overexpressed and pathologically activated in cancer cells. However, the extent to which RAD18 shapes cancer genomes and impacts tumorigenesis is unclear. Therefore, we tested the effect of Rad18 status on chemically-induced and oncogene-driven tumorigenesis. In a chemically-induced oral carcinogenesis model, acute (2-16 days) 4NQO-treatment induces expression of Rad18 and TLS polymerase mRNAs in mouse oral epithelial cells prior to emergence of oral squamous cell carcinomas (OSCCs). Chronic (8 week) 4NQO-treatment leads to onset of oral tumors that is accelerated in Rad18 -/- mice when compared with Rad18 +/+ animals. Analysis of OSCC exomes reveals increased levels of G(C)>T(A) transversions in Rad18 -/- tumors when compared with Rad18 +/+ . Therefore, Rad18 promotes error-free bypass of 4NQO-induced DNA lesions and suppresses 4NQO-induced oral carcinogenesis. In a Kras G12D -induced lung carcinogenesis model, Rad18 -deficiency did not affect rates or incidence of oncogene-induced lung tumors or mutations. Taken together, we demonstrate that Rad18 has context-specific tumor-suppressive activity. Given the prevalence of 4NQO-like environmental exposures, RAD18 is highly likely to shape human cancer genomes and perhaps influence other aspects of the tumorigenic process.
- 19 December 2024
- Published by Taylor & Francis in Statistics in Biopharmaceutical Research
- Vol. 17 (3) , 404-416
Direct Estimation for Commonly Used Pattern-Mixture Models in Clinical Trials
- 19 December 2024
- Published by Taylor & Francis in Statistics in Biopharmaceutical Research
- Vol. 17 (3) , 404-416
Direct Estimation for Commonly Used Pattern-Mixture Models in Clinical Trials
- Open Access
- 4 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-20
Trans-lesion synthesis and mismatch repair pathway crosstalk defines chemoresistance and hypermutation mechanisms in glioblastoma
Almost all Glioblastoma (GBM) are either intrinsically resistant to the chemotherapeutical drug temozolomide (TMZ) or acquire therapy-induced mutations that cause chemoresistance and recurrence. The genome maintenance mechanisms responsible for GBM chemoresistance and hypermutation are unknown. We show that the E3 ubiquitin ligase RAD18 (a proximal regulator of TLS) is activated in a Mismatch repair (MMR)-dependent manner in TMZ-treated GBM cells, promoting post-replicative gap-filling and survival. An unbiased CRISPR screen provides an aerial map of RAD18-interacting DNA damage response (DDR) pathways deployed by GBM to tolerate TMZ genotoxicity. Analysis of mutation signatures from TMZ-treated GBM reveals a role for RAD18 in error-free bypass of O6mG (the most toxic TMZ-induced lesion), and error-prone bypass of other TMZ-induced lesions. Our analyses of recurrent GBM patient samples establishes a correlation between low RAD18 expression and hypermutation. Taken together we define molecular underpinnings for the hallmark tumorigenic phenotypes of TMZ-treated GBM.
- 4 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-20
Open AccessTrans-lesion synthesis and mismatch repair pathway crosstalk defines chemoresistance and hypermutation mechanisms in glioblastoma
Almost all Glioblastoma (GBM) are either intrinsically resistant to the chemotherapeutical drug temozolomide (TMZ) or acquire therapy-induced mutations that cause chemoresistance and recurrence. The genome maintenance mechanisms responsible for GBM chemoresistance and hypermutation are unknown. We show that the E3 ubiquitin ligase RAD18 (a proximal regulator of TLS) is activated in a Mismatch repair (MMR)-dependent manner in TMZ-treated GBM cells, promoting post-replicative gap-filling and survival. An unbiased CRISPR screen provides an aerial map of RAD18-interacting DNA damage response (DDR) pathways deployed by GBM to tolerate TMZ genotoxicity. Analysis of mutation signatures from TMZ-treated GBM reveals a role for RAD18 in error-free bypass of O6mG (the most toxic TMZ-induced lesion), and error-prone bypass of other TMZ-induced lesions. Our analyses of recurrent GBM patient samples establishes a correlation between low RAD18 expression and hypermutation. Taken together we define molecular underpinnings for the hallmark tumorigenic phenotypes of TMZ-treated GBM.
- Open Access
- 16 October 2023
- Published by Springer Nature in Research Square
Trans-Lesion Synthesis and Mismatch Repair Pathway Crosstalk Defines Chemoresistance and Hypermutation Mechanisms in Glioblastoma
Almost all Glioblastoma (GBM) are either intrinsically resistant to the chemotherapeutical drug temozolomide (TMZ) or acquire therapy-induced mutations that cause chemoresistance and recurrence. The genome maintenance mechanisms responsible for GBM chemoresistance and hypermutation are unknown. We show that the E3 ubiquitin ligase RAD18 (a proximal regulator of TLS) is activated in a Mismatch repair (MMR)-dependent manner in TMZ-treated GBM cells, promoting post-replicative gap-filling and survival. An unbiased CRISPR screen provides a new aerial map of RAD18-interacting DNA damage response (DDR) pathways deployed by GBM to tolerate TMZ genotoxicity. Analysis of mutation signatures from TMZ-treated GBM reveals a role for RAD18 in error-free bypass of O6mG (the most toxic TMZ-induced lesion), and error-prone bypass of other TMZ-induced lesions. Our analyses of recurrent GBM patient samples establishes a correlation between low RAD18 expression and hypermutation. Taken together we define novel molecular underpinnings for the hallmark tumorigenic phenotypes of TMZ-treated GBM.
- 16 October 2023
- Published by Springer Nature in Research Square
Open AccessTrans-Lesion Synthesis and Mismatch Repair Pathway Crosstalk Defines Chemoresistance and Hypermutation Mechanisms in Glioblastoma
Almost all Glioblastoma (GBM) are either intrinsically resistant to the chemotherapeutical drug temozolomide (TMZ) or acquire therapy-induced mutations that cause chemoresistance and recurrence. The genome maintenance mechanisms responsible for GBM chemoresistance and hypermutation are unknown. We show that the E3 ubiquitin ligase RAD18 (a proximal regulator of TLS) is activated in a Mismatch repair (MMR)-dependent manner in TMZ-treated GBM cells, promoting post-replicative gap-filling and survival. An unbiased CRISPR screen provides a new aerial map of RAD18-interacting DNA damage response (DDR) pathways deployed by GBM to tolerate TMZ genotoxicity. Analysis of mutation signatures from TMZ-treated GBM reveals a role for RAD18 in error-free bypass of O6mG (the most toxic TMZ-induced lesion), and error-prone bypass of other TMZ-induced lesions. Our analyses of recurrent GBM patient samples establishes a correlation between low RAD18 expression and hypermutation. Taken together we define novel molecular underpinnings for the hallmark tumorigenic phenotypes of TMZ-treated GBM.
- 14 February 2021
- Published by Wiley in Statistics in Medicine
- Vol. 40 (8) , 1930-1946
Learning latent heterogeneity for type 2 diabetes patients using longitudinal health markers in electronic health records
Electronic health records (EHRs) from type 2 diabetes (T2D) patients consist of longitudinally and sparsely measured health markers at clinical encounters. Our goal is to use such data to learn latent patterns that can inform patient's health status related to T2D while accounting for challenges in retrospectively collected EHRs. To handle challenges such as correlated longitudinal measurements, irregular and informative encounter times, and mixed marker types, we propose multivariate generalized linear models to learn latent patient subgroups. In our model, covariate effects were time‐dependent and latent Gaussian processes were introduced to model between‐marker correlations over time. Using inferred latent processes, we integrated the irregularly measured health markers of mixed types into composite scores and applied hierarchical clustering to learn latent subgroup structures among T2D patients. Application to an EHR dataset of T2D patients showed different trends of age, sex, and race effects on hypertension/high blood pressure, total cholesterol, glycated hemoglobin, high‐density lipoprotein, and medications. The associations among these markers varied over time during the study window. Clustering results revealed four subgroups, each with distinct health status. The same patterns were further confirmed using new EHR records of the same cohort. We developed a novel latent model to integrate longitudinal health markers in EHRs and characterize patient latent heterogeneities. Analysis indicated that there were distinct subgroups of T2D patients, suggesting that effective healthcare managements for these patients should be performed separately for each subgroup.
- 14 February 2021
- Published by Wiley in Statistics in Medicine
- Vol. 40 (8) , 1930-1946
Learning latent heterogeneity for type 2 diabetes patients using longitudinal health markers in electronic health records
Electronic health records (EHRs) from type 2 diabetes (T2D) patients consist of longitudinally and sparsely measured health markers at clinical encounters. Our goal is to use such data to learn latent patterns that can inform patient's health status related to T2D while accounting for challenges in retrospectively collected EHRs. To handle challenges such as correlated longitudinal measurements, irregular and informative encounter times, and mixed marker types, we propose multivariate generalized linear models to learn latent patient subgroups. In our model, covariate effects were time‐dependent and latent Gaussian processes were introduced to model between‐marker correlations over time. Using inferred latent processes, we integrated the irregularly measured health markers of mixed types into composite scores and applied hierarchical clustering to learn latent subgroup structures among T2D patients. Application to an EHR dataset of T2D patients showed different trends of age, sex, and race effects on hypertension/high blood pressure, total cholesterol, glycated hemoglobin, high‐density lipoprotein, and medications. The associations among these markers varied over time during the study window. Clustering results revealed four subgroups, each with distinct health status. The same patterns were further confirmed using new EHR records of the same cohort. We developed a novel latent model to integrate longitudinal health markers in EHRs and characterize patient latent heterogeneities. Analysis indicated that there were distinct subgroups of T2D patients, suggesting that effective healthcare managements for these patients should be performed separately for each subgroup.